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albumin changed over time on PD, although they were
closely linked to plasma IL-6 levels. A strong positive cor-
relation was found between D/P creat and dialysate IL-6
(rho = 0.77, p < 0.0001) at baseline, but not at 1 year. In
contrast, there was a significant correlation between D/P
creat and dialysate sIL-6R (rho = 0.39, p < 0.05) at 1 year,
but not at baseline. At 1 year, 17 patients with increasing
PSTR had higher increases in dialysate IL-6 (28 ± 26 vs –21 ±
78 pg/mL, p < 0.05) and levels of dialysate sIL-6R (693 ±
392 vs 394 ± 274 pg/mL, p = 0.05) compared to patients
with stable PSTR (n = 11). Patients who had peritonitis pre-
sented higher baseline serum IL-6 concentration (6.8 ±
1.0 pg/mL) compared with patients without peritonitis
(4.0 ± 0.6 pg/mL, p < 0.05). Finally, both at baseline and
after 1 year, there were significant correlations between
plasma and dialysate IL-6 (rho = 0.46, p < 0.05, and rho =
0.40, p < 0.05) respectively.
¤¤
¤¤
¤ Conclusions: These findings indicate that, (1) intraperi-
toneal and systemic inflammation increase in PD patients
during the first year of therapy; (2) intraperitoneal and
systemic inflammation may be interrelated and the IL-6
system may be the link; (3) the IL-6 system (both intra-
peritoneal and systemic) is associated with PSTR, particu-
larly in the early phase of PD treatment, in which small and
large solute transport are linked. Signs of a transition be-
tween acute and chronic inflammation were observed in the
follow-up evaluation. Inflammation may, at least in part,
be responsible for the development of a high PSTR, and this
could be one reason for the high mortality in patients with
high PSTR.
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¤¤
¤¤
¤ Objective: To investigate if intraperitoneal and systemic
interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6R) are
related to each other and to peritoneal solute transport rate
(PSTR).
¤¤
¤¤
¤ Design: Longitudinal study in retrospectively selected
patients.
¤¤
¤¤
¤ Setting: Peritoneal dialysis (PD) unit of a university-
based hospital.
¤¤
¤¤
¤ Patients and Methods: 31 PD patients on treatment with
conventional glucose-based solutions participated in a lon-
gitudinal study. IL-6 and sIL-6R were measured in plasma
and overnight effluent, both at baseline and after 12 ±
2 months on PD. C-reactive protein (CRP) and serum albu-
min were used as surrogate markers of inflammation. PSTR
of small solutes was evaluated using the dialysate-to-
plasma ratio (D/P) of creatinine after a 4-hour dwell; PSTR
of large solutes was evaluated using the 24-hour D/P ratio
of albumin.
¤¤
¤¤
¤ Results: D/P creat increased over time (0.67 ± 0.15 vs
0.80 ± 0.11, p < 0.0001) and correlated to D/P albumin only
at the baseline evaluation. Patients with plasma IL-6 
‡‡
‡‡
‡  me-
dian had higher (p < 0.005) D/P creat at baseline [0.74
(0.62 – 0.87)] compared to patients with IL-6 < median
[0.57 (0.47 – 0.66)]. Dialysate IL-6 at baseline was also
higher (p < 0.05) in patients with plasma IL-6 
‡‡
‡‡
‡  median
[24.7 (16.5 – 38.5) pg/mL] compared to patients with
IL-6 < median [14.1 (10 – 25.7) pg/mL]. Neither CRP nor
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KEY WORDS: Peritoneal solute transport rate; in-
flammation; interleukin-6.
Cytokines orchestrate the inflammatory response, andavailable data suggest that interleukin-6 (IL-6) and
its soluble receptor (sIL-6R) are central regulators of the
inflammatory process (1). Interleukin-6 is a well-known
pleiotropic cytokine that promotes inflammatory events
through the activation and proliferation of lymphocytes,
differentiation of B cells, leukocyte recruitment, and in-
duction of the acute-phase protein response in the liver
(1). Its bioactivity in several sites of the human body is
regulated mainly by sIL-6R. Formation of the sIL-6R/IL-6
complex widens the repertoire of cells responding to IL-6
action (2). Additionally, sIL-6R regulates the transition
between acute and chronic inflammation, suggesting its
involvement in the resolution of the inflammatory pro-
cess due to its agonistic properties (2). Interestingly,
plasma levels of IL-6 are highly correlated with surro-
gate markers of inflammation, such as C-reactive pro-
tein (CRP) and serum albumin (3), and elevated plasma
IL-6 and sIL-6R levels represent major risk factors for
mortality, not only in the general population (4) but also
in hemodialysis (HD) and peritoneal dialysis (PD) pa-
tients (5).
A number of factors prevalent in patients with end-
stage renal disease (ESRD), such as advanced age, hy-
pertension, adiposity, insulin resistance, fluid overload,
and persistent infections, are associated with elevated
plasma IL-6 levels (3). In addition, hypercytokinemia in
PD patients might be attributed to low clearance of in-
flammation mediators, uremia per se, and factors related
to the dialysis procedure, namely subclinical peritonitis
and the bioincompatibility of PD solutions (6). Inflam-
matory changes, such as an increased number of macro-
phages, are often seen in the peritoneum, even in the
absence of peritonitis, indicating that the peritoneum
of the PD patient is a chronically inflamed organ (7).
During PD treatment, thickening of the submesothelial
space and alteration of the microvessel structure are
commonly observed. These morphological alterations
occur concomitantly with functional changes over time
on PD, particularly in patients with higher peritoneal
solute transport rates (PSTRs) for small solutes (8). A
high PSTR has been identified as a frequent cause of PD
technique failure (9) and represents an independent risk
factor for increased mortality in PD patients for reasons
yet to be clarified (10,11). In a previous cross-sectional
study, we observed that patients with high PSTR had
higher plasma levels of IL-6 and higher prevalence of
comorbidities such as diabetes mellitus and peritonitis
(12). Although it has been suggested that PSTRs for small
and large solutes are closely linked, longitudinal infor-
mation regarding the relationship between peritoneal
transport of those solutes is lacking.
During PD, the peritoneal membrane is continuously
exposed to bioincompatible dialysis solutions that con-
tain high concentrations of glucose and glucose degra-
dation products and have low pH and high osmolality, all
of which are potential activators of a proinflammatory
response (13). Significant amounts of IL-6 are present in
drained PD dialysate in much higher concentrations than
in plasma under stable conditions (12), and are increased
shortly before the onset of (14) and during peritonitis
(15), suggesting its local production and reflecting an
intraperitoneal inflammatory state (16). Although intra-
peritoneal IL-6 has been used to evaluate local inflam-
mation, intraperitoneal sIL-6R levels have not previously
been described in the dialysate. Finally, inflammatory
changes of the peritoneum are observed even before the
initiation of PD treatment (8), suggesting that systemic
factors related to uremia may, at least in part, be respon-
sible for histological and functional changes of the ure-
mic peritoneum. Indeed, recent studies performed in
animal models clearly demonstrate the impact of uremia
in peritoneal membrane changes (17). However, clinical
evidence of the links between systemic and intraperito-
neal inflammation remain to be demonstrated.
We hypothesize that signs of inflammation increase
over time on PD, and that intraperitoneal and systemic
inflammation are interrelated and associated with high
PSTR of both small and large solutes. In the present
study, we analyzed the natural evolution of the systemic
and intraperitoneal IL-6 system (IL-6 and sIL-6R) in
31 patients during their first year of PD treatment with
glucose-based solutions. Moreover, we analyzed the pos-
sible links between local and systemic inflammation, and
the association between the IL-6 system and PSTR.
MATERIAL AND METHODS
This was a longitudinal observational study in 31 ret-
rospectively selected patients who underwent PD treat-
ment at the Home Dialysis Unit aff iliated with the
Department of Renal Medicine, Karolinska University
Hospital at Huddinge, Stockholm, Sweden. All patients
treated with conventional glucose-based PD fluids, with
an early evaluation of PSTR (within 1 month after start
of PD), a follow-up evaluation of PSTR after about 1 year,
and simultaneous dialysate and plasma collections
stored in our freezers were included in the study. The
clinical characteristics were retrieved from patient files.
Exclusion criteria were the presence of systemic inflam-
matory disease (e.g., vasculitis, disseminated neopla-
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sia) or peritonitis in the 4 weeks prior to, or after the
evaluation. Mean age was 55 ± 15 years and 58% of the
patients were males. The etiology of ESRD was diabetic
nephropathy in 35%, chronic glomerulonephritis in 23%,
nephrosclerosis in 10%, and unknown or other diseases
in 32% of the cases. The first-month (14 ± 4 days) and
1-year (12 ± 2 months) analysis of PSTR based on the
peritoneal equilibration test (PET) was performed as part
of the routine clinical assessment at least once every
12 months in all patients, independent of their clinical
characteristics. Peritonitis data were retrospectively col-
lected from patients’ records. The Ethics Committee of
the Karolinska Institutet at the Karolinska University
Hospital at Huddinge approved the study and all patients
gave their informed consent to participate.
PERITONEAL TRANSPORT OF SOLUTES
The dialysate-to-plasma ratio (D/P) of creatinine at
4 hours in a standard PET performed with a 2.27% glu-
cose solution was used to assess the peritoneal trans-
port rate for small solutes. Creatinine determinations
were performed by routine procedures in the Department
of Clinical Chemistry, Karolinska University Hospital at
Huddinge, using the Jaffé method. The D/P creat was
corrected for glucose interference in the creatinine assay
using the correction factor derived locally by our labo-
ratory. According to the changes in D/P creat during the
follow-up period, patients were placed into two groups:
increasing PSTR or stable PSTR respectively. To assess the
transport of higher molecular weight solutes, we used
the D/P ratio of albumin in the 24-hour collection per-
formed on the day previous to the PET.
INTERLEUKIN-6 AND sIL-6R
Samples for the determination of circulating and di-
alysate IL-6 and sIL-R were obtained from plasma EDTA
obtained during the PET and overnight dialysate efflu-
ent (from exchanges with 2 L 1.36% glucose dialysis
fluid) from the night preceding the routine PET. Plasma
IL-6 and sIL-6R and dialysate sIL-6R were measured using
an enzyme-linked immunosorbent assay (ELISA; R&D
Systems, Minneapolis, Minnesota, USA). For the sIL-6R
determination, plasma samples were prediluted 40 times
and dialysate samples 5 times. The ELISA plates were read
using ELISA VERSAmax reader (Molecular Devices Corpo-
ration, Sunnyvale, California, USA) and the data were
analyzed with the SoftmaxPRO software (Molecular De-
vices Corporation). Dialysate IL-6 was determined using
an automated immunochemiluminiscence method
(Immulite; DPC Biermann, Bad Nauheim, Germany). The
intra- and interassay variations were 2.3% and 4.2% re-
spectively for IL-6, and 4.3% and 5.2% respectively for
sIL-6R. The detection limit was 0.09 pg/mL for the IL-6
high sensitivity test and 6.5 pg/mL for the sIL-6R test.
OTHER MARKERS OF SYSTEMIC INFLAMMATION
In the same blood sample, serum CRP (immunoneph-
elometric method; minimal detection limit 10 mg/L) and
serum albumin (bromcresol purple method) were deter-
mined and used as markers of systemic inflammation.
Patients were considered inflamed when CRP levels were
above 10 mg/L or albumin below 3.5 g/dL.
STATISTICAL ANALYSIS
Normality of data distribution was assessed using
Kolmogorov–Smirnov test. Values are presented as mean
± standard deviation or as median (interquartile range),
unless otherwise specified. Paired Student’s t-test or
Wilcoxon signed ranked test were used to compare dif-
ferences between baseline and 1-year evaluations. Cor-
relation coefficients were performed by linear regression
analysis for normally distributed variables, and by
Spearman rank correlation test for skewed variables.
Differences between groups were evaluated using the
Mann–Whitney test. Calculations were performed using
the Statistical Package for the Social Sciences (version
10.0; SPSS Inc., Chicago, Illinois, USA). A p value of less
than 0.05 was judged to be significant.
RESULTS
BASELINE CHARACTERISTICS
At the start of PD treatment, mean 4-hour D/P creat
for the entire group was 0.67 ± 0.15 (range 0.44 – 0.95;
median 0.66, interquartile range 0.57 – 0.79). Six pa-
tients were classified as low transporters, 9 as low-aver-
age transporters, 10 as high-average transporters, and
6 as high transporters. Mean 24-hour D/P albumin was
0.14 (range 0.06 – 0.40). Median CRP level was 14.6 mg/L
(range 10 – 44 mg/L) and median albumin level was
3.2 mg/dL (range 2.1 – 4.6 mg/dL) (Table 1). There was
a significant correlation between small solute (D/P creat)
and large solute (D/P albumin) transport (rho = 0.53,
p < 0.005) (Figure 1).
ONE-YEAR CHARACTERISTICS
After the first year of PD treatment, mean D/P creat
was 0.80 ± 0.12 (range 0.61 – 0.96; median 0.80,
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interquartile range 0.72 – 0.86) (Table 1). Three patients
were classified as low-average transporters, 13 as high-
average transporters, and 14 as high transporters. Sev-
enteen (61%) patients had increasing PSTR and 11 (39%)
had stable PSTR compared to the baseline study. The PSTR
increased (p < 0.0001) compared to baseline, but the
same increase was not observed for D/P albumin
(Table 1). Mean 24-hour D/P albumin at the follow-up
evaluation was 0.10 (range 0.02 – 0.22) (Table 1). No
association between transport of small and large mol-
ecules was observed after 12 months on PD (rho = 0.10,
p = NS) (Figure 1). Median CRP level was 14.5 mg/L (range
10 – 77 mg/L) and median serum albumin level was
3.3 mg/dL (range 2.4 – 4.6 mg/dL) (Table 1).
LONGITUDINAL CHANGES IN INFLAMMATION MARKERS AND
SYSTEMIC AND INTRAPERITONEAL IL-6 SYSTEM
No significant changes were observed for CRP and
albumin levels during the evaluation. Median plasma
IL-6 increased during the f irst year on PD, from
3.7 pg/mL (range 2.8 – 6.1 pg/mL) at baseline to
6.5 pg/mL (range 3.4 – 8.25 pg/mL, p < 0.05). Simi-
larly, median dialysate IL-6 was greater after 1 year
(32.8 pg/mL, range 24.6 – 48.2 pg/mL) compared to
baseline (19.7 pg/mL, range 12.6 – 30.0 pg/mL; p <
0.05) (Table 1). In contrast, no changes in either sys-
temic or intraperitoneal sIL-6R levels were observed
over time on PD (Table 1).
TABLE 1
Longitudinal Evolution of Peritoneal Solute Transport Rate, Inflammation Markers, and Plasma and
Dialysate Interleukin-6 (IL-6) System During the First Year of Peritoneal Dialysis
Baseline 1 Year p Value
4-hour D/P creatinine 0.67±0.15 0.80±0.12 <0.0001
24-hour D/P albumin 0.14 (0.06–0.40) 0.10 (0.02–0.22) NS
Plasma IL-6 (pg/mL) 3.7 (2.8–6.1) 6.5 (3.4–8.2) <0.05
Plasma sIL-6R (pg/mL) 53023 (42359–58903) 50382 (40227–56786) NS
C-reactive protein (mg/L) 14.6 (10–44) 14.5 (10–77) NS
Serum albumin (mg/dL) 3.2 (2.1–4.6) 3.3 (2.4–4.6) NS
Dialysate IL-6 (pg/mL) 19.7 (12.6–30.0) 32.8 (24.6–48.2) <0.05
Dialysate sIL-6R (pg/mL) 491 (358–741) 584 (236–907) NS
D/P IL-6 6.9 6.1 NS
D/P sIL-6R 0.012 0.012 NS
D/P = dialysate-to-plasma ratio; sIL-6R = soluble IL-6 receptor; NS = not significant.
Values are presented as mean±SE or median and range, accordingly.
Figure 1 — Correlation between low and high molecular weight solute transport at baseline and after 12 months on peritoneal
dialysis, showing that dialysate-to-plasma ratio (D/P) of creatinine and albumin were significantly correlated only at the baseline
evaluation. ns = not significant.
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SYSTEMIC INFLAMMATORY STATUS AND PERITONEAL
TRANSPORT
Patients with plasma IL-6 ‡  median at baseline had
higher baseline values of 4-hour D/P creat [0.74 (0.62 –
0.87) vs 0.57 (0.47 – 0.66), p < 0.005] compared to pa-
tients with IL-6 < median. Changes in plasma IL-6 tended
to correlate with changes in D/P creat (r = 0.35, p = 0.07),
although this was not statistically significant. At base-
line, there was a significant correlation between plasma
IL-6 and 4-hour D/P creat (rho = 0.47, p < 0.05), but not
between plasma sIL-6R and 4-hour D/P creat (rho = –0.17,
p = NS). Additionally, plasma IL-6 was significantly cor-
related to D/P albumin at baseline. After 1 year, plasma
IL-6 was no longer significantly correlated with D/P creat
(rho = 0.16), but remained significantly correlated to D/P
albumin (rho = 0.38, p < 0.05). Plasma sIL-6R remained,
similarly to baseline, non correlated with D/P creat (rho =
0.36, p = NS). There were no significant associations be-
tween serum CRP and albumin levels with PSTR of small
solutes, whereas serum albumin was associated with D/P
albumin, both at baseline (rho = –0.42, p < 0.01) and
after 12 months (rho = –0.51, p < 0.001). A summary of
the associations between PSTR and inflammation mark-
ers is presented in Table 2.
With the exception of the lack of correlation between
baseline serum albumin and IL-6, all inflammation mark-
ers were correlated to each other, both at the baseline
(CRP vs IL-6: rho = 0.35, p < 0.05; CRP vs serum albumin:
rho = –0.47, p < 0.05) and at 12 months (CRP vs IL-6:
rho = 0.70, p < 0.0001; CRP vs serum albumin: rho =
–0.50, p < 0.05; serum albumin vs IL-6: rho = –0.47, p <
0.001).
CORRELATIONS BETWEEN INTRAPERITONEAL IL-6 SYSTEM
AND PSTR
The associations between PSTR and the intraperito-
neal IL-6 system are presented in Figures 2 and 3. At
baseline, there was a strong positive correlation between
dialysate IL-6 and D/P creat (rho = 0.77, p < 0.0001), but
not between dialysate sIL-6R and D/P creat (rho = 0.30,
p = NS) (Figure 2). In addition, dialysate IL-6 also corre-
lated with D/P albumin (rho = 0.49, p < 0.005). In con-
trast to baseline, after 1 year there was no significant
correlation between dialysate IL-6 and D/P creat (rho =
0.14, p = NS), although the association between dialy-
sate IL-6 and D/P albumin remained significant (rho =
0.44, p < 0.005). A significant positive correlation be-
tween 1-year sIL-6R and 1-year D/P creat (rho = 0.39,
p < 0.05) was present (Figure 3). Changes in dialysate
sIL-6R tended to be associated with changes in D/P creat
(r = 0.36, p = 0.07), although this was not statistically
significant.
INCREASING VERSUS STABLE PSTR
At the 1-year evaluation (Figure 4), patients with in-
creasing PSTR had higher levels of dialysate sIL-6R
[594 pg/mL (range 341 – 976 pg/mL) vs 388 pg/mL
(range 206 – 618 pg/mL), p = 0.05] compared to patients
with stable PSTR (Figure 4), and there was a significantly
higher increase in dialysate IL-6 [19.9 pg/mL (range
15.9 – 80.2 pg/mL) vs –1.4 pg/mL (range –168.9 to
66.5 pg/mL), p < 0.05].
PERITONITIS EPISODES
Ten patients had 12 episodes of peritonitis during fol-
low-up. No differences in PSTR in patients with and with-
out peritonitis episodes were observed. Similarly, there
were no differences in serum CRP and serum albumin lev-
els in patients with and patients without peritonitis. In-
terestingly, patients who later developed peritonitis
presented a higher baseline serum IL-6 concentration
(6.8 ± 1.0 pg/mL) compared with patients without peri-
tonitis (4.0 ± 0.6 pg/mL, p < 0.05) (Figure 5). Moreover,
patients with peritonitis had higher dialysate IL-6 con-
centration (58.4 ± 12.6 pg/mL) compared with patients
without peritonitis (20.3 ± 8.7 pg/mL, p = 0.07) at the
TABLE 2
Correlations Between Plasma Inflammation Markers and Peritoneal Transport Rate of Small and Large Solutes
 Baseline 1 year
 D/P creatinine D/P albumin D/P creatinine D/P albumin
Plasma IL-6 rho=0.47, p<0.05 rho=0.39, p<0.05 rho=0.16, p=NS rho=0.38, p<0.05
Plasma sIL-6R rho=–0.17, p=NS rho=0.06, p=NS rho=0.36, p=NS rho=0.001, p=NS
C-reactive protein rho=0.11, p=NS rho=0.16, p=NS rho=0.18, p=NS rho=0.14, p=NS
Albumin rho=–0.18, p=NS rho=–0.42, p<0.01 rho=0.28, p=NS rho=–0.51, p<0.001
IL-6 = interleukin-6; sIL-6R = soluble interleukin-6 receptor; D/P = dialysate-to-plasma ratio; NS = not significant.
Rho is Spearman coefficient.
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baseline evaluation, but this difference did not reach
statistical significance (Figure 5).
RELATIONSHIP BETWEEN SYSTEMIC AND INTRAPERITONEAL
IL-6 SYSTEM
The dialysate IL-6 concentration was several-fold
higher than the plasma IL-6 concentration, while the
dialysate sIL-6R level was markedly lower than the plasma
sIL-6R level (Table 1). Plasma IL-6 and dialysate IL-6 lev-
els were significantly correlated, both at baseline (rho =
0.46, p < 0.05) and after 1 year (rho = 0.40, p < 0.05)
(Figure 6). Accordingly, patients with baseline plasma
IL-6 ‡  median had higher baseline levels of dialysate IL-6
(24.7 pg/mL, range 16.5 – 38.5 pg/mL) compared to
patients with plasma IL-6 < median (14.1 pg/mL, range
10.0 – 25.7 pg/mL) (p < 0.05). This association was not
present at the follow-up evaluation. On the other hand,
there were no statistically significant correlations be-
tween plasma sIL-6R and dialysate sIL-6R, at baseline
(rho = –0.25) or at 1 year (rho = 0.03). Since the con-
centration of sIL-6R was much lower in dialysate than in
plasma, we analyzed if the dialysate concentration of
sIL-6R was only a reflection of transport from circula-
tion. Therefore, we compared D/P sIL-6R (55 kD) to D/P
albumin (67 kD) and found no significant correlation be-
tween them both at baseline or at 12 months, suggest-
ing that factors other than transport from circulation are
involved in the appearance of sIL-6R in dialysate.
DISCUSSION
The present study is the first description of the natu-
ral evolution of the systemic and intraperitoneal levels
of components of the IL-6 system (IL-6 and sIL-6R) dur-
ing the first year on PD. The results of this longitudinal
evaluation indicate that intraperitoneal and systemic
inflammation increase in patients treated with conven-
tional glucose-based PD solutions during the first year
of PD, and that intraperitoneal and systemic inflamma-
Figure 2 — Associations between dialysate levels of interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R) with transport
of small and large solutes in the baseline evaluation. Only dialysate levels of IL-6 were significantly correlated to peritoneal solute
transport rate. D/P = dialysate-to-plasma ratio.
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tion may be interrelated, particularly during the early
phase of PD therapy. The alterations in the IL-6 system
were closely associated with alterations in PSTR. We also
describe that small and large solute transport rates are
linked at baseline, but disconnected after 1 year on PD.
Finally, signs of systemic inflammation appeared to be
linked to increased risk for peritonitis. These findings,
therefore, provide support for the hypothesis that in-
flammation may play a central role in the development
of high PSTR, and that this involvement may at least
partly explain the high mortality and morbidity observed
in patients with high PSTR.
Interleukin-6 is a 22 – 27 kDa polypeptide secreted
from activated monocytes, macrophages, fibroblasts,
adipocytes, and endothelial cells in response to various
stimuli, such as tumor necrosis factor alpha, IL-1b , bac-
terial endotoxins, and oxidative stress. It is notable that,
whereas most other cytokines act via paracrine/auto-
crine mechanisms, the major effects of IL-6 are medi-
ated by its concentration in the circulation, and thus IL-6
can exert its effects at sites distinct and far from its ori-
gin. Circulating IL-6 can be detected in healthy individu-
als in the 1 pg/mL range and it is markedly elevated in
most ESRD patients (18). Plasma IL-6 is considered a sur-
rogate marker of systemic inflammation and its levels
are strongly correlated with plasma CRP levels. There is
now epidemiological information linking plasma IL-6
concentrations to cardiovascular morbidity and mortal-
ity in non-renal patient groups (4) and also in HD and
PD patients (5). In the present study, we show an asso-
ciation between plasma IL-6 and PSTR, as seen not only
by the significant correlation between plasma IL-6 and
D/P creat, but also by the increased PSTR in inflamed
patients. Interestingly, this association between sys-
temic inflammation and PSTR was observed only at the
early phase of PD treatment and not after 1 year of di-
alysis therapy.
Interleukin-6 exhibits its action via a receptor com-
plex consisting of a specific IL-6 receptor and a signal
transducing subunit (gp130). The soluble forms of both
Figure 3 — Associations between the dialysate levels of interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R) with trans-
port of small and large solutes in the follow-up evaluation. D/P = dialysate-to-plasma ratio.
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Figure 4 — Patients with increasing peritoneal solute transport rate (PSTR) had more pronounced changes of dialysate interleukin-
6 (IL-6) (p < 0.05) and higher dialysate levels of soluble interleukin-6 receptor (sIL-6R) (p = 0.05). Box plot representation: 75%
and 25% percentiles, median, and maximum and minimum values.
Figure 5 — Baseline plasma and dialysate interleukin-6 (IL-6) levels in relation to peritonitis episodes.
Figure 6 — Plasma and dialysate levels of interleukin-6 (IL-6) at the baseline and 12-month evaluations show significant positive
correlations between systemic and local intraperitoneal inflammation.
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receptor components are generated by shedding; they
reach the circulation and then participate in the regula-
tion of IL-6 activity. While sIL-6R binds to IL-6 in plasma,
expanding the half-life of the IL-6/sIL-6R complex and
extending IL-6 bioactivity to organs containing the
gp130 membrane-binding site (1), circulating gp130 acts
as an antagonist of IL-6 biological functions, namely
activation of the acute-phase response, decreasing ap-
petite, hypercatabolism, hypercoagulability, and accel-
erated atherosclerosis (2). Furthermore, the formation
of the sIL-6R/IL-6 complex appears to be important in
the resolution of inflammation (19). Similarly to IL-6,
sIL-6R represents a risk factor for mortality in dialysis
patients (5), but the precise role of plasma and dialy-
sate sIL-6R remains to be determined.
In the present study, plasma IL-6 levels significantly
increased throughout the observation period, indicat-
ing an increase in inflammatory activity over time on di-
alysis. Potential causes for our f indings are loss of
residual renal function (RRF) and ageing [since they ap-
pear to be strongly correlated with systemic inflamma-
tion (20)], and clinical events occurring during the
course of PD treatment. Because of the cross-sectional
design of this study, it is not possible to draw definitive
conclusions about the causes of the increasing inflam-
matory status in these patients. In this longitudinal
evaluation, we confirmed our previous cross-sectional
observation that plasma IL-6 appears to be associated
with PSTR (12), and found that this occurs mainly in the
early phase of PD treatment. Interestingly, at the base-
line evaluation, PSTRs of small and large solutes were
interrelated, but this was not observed at follow-up.
After 1 year of treatment, no correlation between sys-
temic inflammation and PSTR of small solutes was
present, but the link between plasma IL-6 and PSTR of
albumin was still present. Reinforcing these results, we
also demonstrated that patients showing more signs of
systemic inflammation at the start of PD treatment pre-
sented higher PSTRs concomitantly with higher dialysate
IL-6 levels.
It is likely that cumulative exposure to bioincompati-
ble solutions may play a role in the persistent and in-
creasing intraperitoneal inflammatory response, and
therefore in the regulation of peritoneal permeability.
Permeability changes have been observed following the
administration of vasoactive drugs, such as nitroprus-
side (21), and during severe inflammation, such as peri-
tonitis (15). In our study, intraperitoneal levels of IL-6
were several-fold higher than plasma concentrations,
indicating local production of IL-6. Intraperitoneal pro-
duction of IL-6 can probably be attributed to mesothe-
lial cells (22), macrophages, or endothelial cells (23). It
appears from recent studies that IL-6 is a central media-
tor of the inflammatory response in the peritoneal cav-
ity. Hurst et al. (19), combining clinical and experimental
evidence, recently showed that IL-6 controls the pattern
of leukocyte recruitment during inflammation. During
the peritoneal inflammatory response, the intraperito-
neal actions of IL-6 and sIL-6R are tightly linked and are
particularly regulated by mesothelial cells. These cells
by nature do not possess a cognate IL-6 receptor and
therefore require the presence of the sIL-6R to be respon-
sive to IL-6. According to Hurst et al. (19), IL-6 partici-
pates in the early phase of the intraper itoneal
inflammatory response, which is neutrophil mediated,
while the later appearance of sIL-6R is essential for the
resolution of the inflammatory process.
In our study, the association between 12-month di-
alysate sIL-6R and PSTR, in contrast to the early asso-
ciation between dialysate IL-6 and PSTR, hypothetically
suggests that the transition in cytokine effluent produc-
tion may reflect two distinct phases in the intraperito-
neal inflammatory response, namely, an early
(neutrophil mediated) and a late (mononuclear leuko-
cyte mediated) phase, which may reflect a resolved in-
f lammation process. However, to conf irm this
hypothesis, it will be necessary to perform cytokine mea-
surements during active inflammation (i.e., during
peritonitis).
It is important to clarify that in vitro studies demon-
strated higher IL-6 production in response to exposure
to more biocompatible dialysis solutions, in which case
IL-6 is presumably a marker of cell vitality (24,25). In
contrast, ex vivo studies showed lower cytokine produc-
tion when more biocompatible solutions were used (26).
In fact, recent clinical studies using a bicarbonate/lac-
tate solution have shown that the intraperitoneal cellu-
lar response to the more biocompatible solution leads
to lower dialysate levels of IL-6 in comparison to stan-
dard solutions, suggesting a reduced inflammatory re-
sponse (27). Also, in a clinical evaluation, Fujimori et al.
(28) compared the effects of 1.36%, 2.27%, and 3.86%
glucose solutions on dialysate levels of IL-6 and showed
that a higher glucose concentration in dialysis fluid in-
duced higher production of intraperitoneal IL-6. There-
fore, in accordance with Cooker et al. (27), we propose
that intraperitoneal IL-6 concentration may be regarded
a marker of ongoing intraperitoneal inflammation. Simi-
larly to what was observed for systemic inflammation,
the association between dialysate IL-6 and PSTR appears
to be occurring mainly in the initial phase of PD treat-
ment, although intraperitoneal IL-6 was associated with
peritoneal permeability to large solutes in a previous
cross-sectional study (14), as well as in our own
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cross-sectional analysis (12). In the follow-up investi-
gation, we observed an association between sIL-6R and
PSTR, and noted that patients with increasing PSTR pre-
sented higher dialysate levels of sIL-6R at 1 year. More-
over, the fact that patients with increasing PSTR
presented greater changes in dialysate IL-6 levels dur-
ing the first year of PD, and the observation of an asso-
ciation between changes in dialysate IL-6 and changes
in RRF, the importance of the links between RRF, inflam-
mation, and changes in PSTR are reinforced, as observed
by Chung et al. (29).
Another novel finding of our study is the association
between systemic and local inflammation, based on the
correlation between plasma and dialysate IL-6. This as-
sociation appears to occur both in the initial phase of PD
treatment and at a later phase. Whether systemic inflam-
mation causes local inflammation or intraperitoneal in-
flammatory activation leads to a systemic response needs
further evaluation.
Also of interest, we observed a discrepancy between
the PSTRs of small and large solutes in the baseline and
follow-up evaluations, and local and systemic inflamma-
tion (represented by both plasma and dialysate IL-6 lev-
els) appeared to be consistently linked to the PSTR of
albumin, irrespectively of the time of evaluation. This
finding provides evidence connecting IL-6 to increased
peritoneal leakage of proteins, which may reflect
endothelial dysfunction. In contrast, the PSTR of small
solutes was related to IL-6 only at baseline, but in the
follow-up evaluation no associations were observed, in-
dicating that inflammation may not be directly linked to
the high PSTR that develops after long-term PD. The in-
creased PSTR (based on small solute transport) may in-
dicate dif ferent mechanisms of solute transport,
depending on the moment when it is evaluated. Our re-
sults support the hypothesis that there may exist two
distinct types of high transporters (30), namely, the early
inherent high transporter (associated with high comor-
bidity, inflammation, and protein leakage) and the late
acquired high transporter (not associated with
comorbidities, inflammation, and protein leakage). To
advance understanding of the high mortality of patients
with high PSTR, further studies need to confirm our pre-
liminary data.
It is important to emphasize some significant limita-
tions of this study. The retrospective selection, the low
number of patients included in this analysis, and the
short follow-up limit interpretation of the results, par-
ticularly in the subgroup analysis. Our observations need
to be confirmed in prospective studies, performed in a
large number of patients, before definitive conclusions
can be drawn. On the other hand, clinical observational
studies are important “hypothesis generators.” Addi-
tional experimental studies (including in vitro and ani-
mal studies) will need to address variables that were not
controlled in the present study.
In summary, our findings indicate that intraperito-
neal and systemic inflammation increase over time on
PD and are closely interrelated. Whether or not intra-
peritoneal inflammation reflects in systemic inflamma-
tory activity, or if systemic inflammation causes an
intraperitoneal inflammatory state, remains to be inves-
tigated in an appropriately designed study. The IL-6 sys-
tem is associated with PSTR of both small and large
molecules, IL-6 particularly in the early phase and sIL-6R
in the later stage of PD treatment. In conclusion, inflam-
mation may, at least in part, be linked to the develop-
ment of a high PSTR, and this may contribute to the
previously reported high mortality in high-transport PD
patients.
REFERENCES
1. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM.
The soluble interleukin 6 receptor: mechanisms of pro-
duction and implications in disease. FASEB J 2001; 15:
43–58.
2. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP.
The pathophysiologic roles of interleukin-6 in human dis-
ease. Ann Intern Med 1998; 128:127–37.
3. Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P.
Update on interleukin-6 and its role in chronic renal fail-
ure. Nephrol Dial Transplant 2003; 18:1042–5.
4. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma
concentration of interleukin-6 and the risk of future myo-
cardial infarction among apparently healthy men. Circu-
lation 2000; 101:1767–72.
5. Pecoits-Filho R, Bárány P, Lindholm B, Heimbürger O,
Stenvinkel P. Interleukin-6 is an independent predictor
of mortality in patients starting dialysis treatment.
Nephrol Dial Transplant 2002; 17:1684–8.
6. Stenvinkel P, Chung SH, Heimbürger O, Lindholm B. Mal-
nutrition, inflammation, and atherosclerosis in peritoneal
dialysis patients. Perit Dial Int 2001; 21(Suppl 3):S157–62.
7. Di Paolo N, Sacchi G. Atlas of peritoneal histology. Perit
Dial Int 2000; 20(Suppl 3):S5–96.
8. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M,
Newman GR, et al. Morphologic changes in the peritoneal
membrane of patients with renal disease. J Am Soc Nephrol
2002; 13:470–9.
9. Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR,
Oreopoulos DG, Page D. Increased peritoneal membrane
transport is associated with decreased patient and tech-
nique survival for continuous peritoneal dialysis patients.
The Canada-USA (CANUSA) Peritoneal Dialysis Study
Group. J Am Soc Nephrol 1998; 9:1285–92.
 by on O
ctober 20, 2010 
w
w
w
.pdiconnect.com
D
ow
nloaded from
 
63
PDI JANUARY 2006 – VOL. 26, NO. 1 SYSTEMIC AND IP IL-6 SYSTEM DURING THE FIRST YEAR OF PD
10. Cueto-Manzano AM, Correa-Rotter R. Is high peritoneal
transport rate an independent risk factor for CAPD mor-
tality? Kidney Int 2000; 57:314–20.
11. Chung SH, Chu WS, Lee HA, Kim YH, Lee IS, Lindholm B,
et al. Peritoneal transport characteristics, comorbid dis-
eases and survival in CAPD patients. Perit Dial Int 2000;
20:541–7.
12. Pecoits-Filho R, Araujo MR, Lindholm B, Stenvinkel P,
Abensur H, Romao JE Jr, et al. Plasma and dialysate IL-6
and VEGF concentrations are associated with high perito-
neal solute transport rate. Nephrol Dial Transplant 2002;
17:1480–6.
13. Libetta C, De Nicola L, Rampino T, De Simone W, Memoli
B. Inflammatory effects of peritoneal dialysis: evidence
of systemic monocyte activation. Kidney Int 1996; 49:
506–11.
14. Zemel D, Betjes MG, Dinkla C, Struijk DG, Krediet RT. Analy-
sis of inflammatory mediators and peritoneal permeabil-
ity to macromolecules shortly before the onset of overt
peritonitis in patients treated with CAPD. Perit Dial Int
1995; 15:134–41.
15. Lai KN, Lai KB, Lam CW, Chan TM, Li FK, Leung JC. Changes
of cytokine profiles during peritonitis in patients on con-
tinuous ambulatory peritoneal dialysis. Am J Kidney Dis
2000; 35:644–52.
16. Breborowicz A, Oreopoulos DG. Evidence for the presence
of chronic inflammation during peritoneal dialysis: thera-
peutic implications. Perit Dial Int 1997; 17(Suppl 2):
S37–41.
17. Combet S, Ferrier ML, Van Landschoot M, Stoenoiu M,
Moulin P, Miyata T, et al. Chronic uremia induces perme-
ability changes, increased nitric oxide synthase expres-
sion, and structural modifications in the peritoneum. J Am
Soc Nephrol 2001; 12:2146–57.
18. Stenvinkel P, Bárány P, Heimbürger O, Pecoits-Filho R,
Lindholm B. Mortality, malnutrition, and atherosclerosis
in ESRD: what is the role of interleukin-6? Kidney Int Suppl
2002; 80:103–8.
19. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi
S, Yamamoto N, et al. IL-6 and its soluble receptor orches-
trate a temporal switch in the pattern of leukocyte recruit-
ment seen during acute inflammation. Immunity 2001;
14:705–14.
20. Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M,
Fehrman-Ekholm I, Lindholm B, et al. Associations be-
tween circulating inflammatory markers and residual renal
function in CRF patients. Am J Kidney Dis 2003; 41:
1212–18.
21. Wang T, Cheng HH, Heimbürger O, Bergström J, Lindholm
B. Vasodilatation by intraperitoneal addition of nitroprus-
side is not a model for high peritoneal transport. Adv Perit
Dial 1999; 15:53–9.
22. Witowski J, Jorres A, Coles GA, Williams JD, Topley N. Su-
perinduction of IL-6 synthesis in human peritoneal me-
sothelial cells is related to the induction and stabilization
of IL-6 mRNA. Kidney Int 1996; 50:1212–23.
23. Serre AF, Marie C, Beaujon G, Betail G, Cavaillon JM, Deteix
P. Variations of cytokine levels and production in CAPD
patients. Int J Artif Organs 1997; 20:614–21.
24. Plum J, Schoenicke G, Grabensee B. Osmotic agents and
buffers in peritoneal dialysis solution: monocyte cytokine
release and in vitro cytotoxicity. Am J Kidney Dis 1997; 30:
413–22.
25. Topley N, Williams JD. Effect of peritoneal dialysis on
cytokine production by peritoneal cells. Blood Purif 1996;
14:188–97.
26. Mackenzie RK, Jones S, Moseley A, Holmes CJ, Argyle R,
Williams JD, et al. In vivo exposure to bicarbonate/lac-
tate- and bicarbonate-buffered peritoneal dialysis fluids
improves ex vivo peritoneal macrophage function. Am J
Kidney Dis 2000; 35:112–21.
27. Cooker L, Luneburg P, Holmes CJ, Topley N. Dialysate lev-
els of IL-6 and VEGF in patients using bicarbonate/lactate-
based peritoneal dialysis solutions [Abstract]. Perit Dial
Int 2001; 21(Suppl 2):S18.
28. Fujimori A, Naito H, Miyazaki T, Azuma M, Hashimoto S,
Horikawa S, et al. Elevation of interleukin 6 in the dialy-
sate reflects peritoneal stimuli and deterioration of peri-
toneal function. Nephron 1996; 74:471–2.
29. Chung SH, Heimburger O, Stenvinkel P, Bergstrom J,
Lindholm B. Association between inflammation and
changes in residual renal function and peritoneal trans-
port rate during the first year of dialysis. Nephrol Dial
Transplant 2001; 16:2240–5.
30. Pecoits-Filho R, Stenvinkel P, Wang AY, Heimbürger O,
Lindholm B. Chronic inflammation in peritoneal dialysis:
the search for the holy grail? Perit Dial Int 2004; 24:
327–39.
 by on O
ctober 20, 2010 
w
w
w
.pdiconnect.com
D
ow
nloaded from
 
